Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRINCIPLE home-treatment platform trial for COVID-19
ISRCTN86534580Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Mar 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of favipiravir, ivermectin, colchicine, budesonide, doxycycline and 2 more in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by University of Oxford. Primary endpoints: Time to self-reported recovery, Hospitalisation and/or death and 1 more. Started Mar 2020; status: completed.
02
Drugs
favipiravirivermectincolchicinebudesonidedoxycycline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN86534580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86534580.